Related Experiment Video

Updated: Aug 1, 2026

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
07:08

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status

Published on: October 20, 2016

Ataxia with isolated vitamin E deficiency: a clinical, biochemical and genetic diagnosis

G Alex1, M R Oliver, K J Collins

  • 1Department of Gastroenterology, Child Development and Rehabilitation, Royal Children's Hospital, Parkville, Victoria, Australia. G.Alex@anatomy.unimelb.edu.au

Journal of Paediatrics and Child Health
|October 19, 2000
PubMed

Insights

This study reports a case of ataxia due to isolated vitamin E deficiency caused by a TTPA gene mutation. Early vitamin E treatment can prevent further neurological damage in affected children.

Area of Science:

  • Neurogenetics
  • Nutritional Neuroscience

Background:

  • Ataxia is a neurological sign often associated with various conditions.
  • Isolated vitamin E deficiency is a rare cause of neurodegeneration.
  • Genetic factors can predispose individuals to metabolic and neurological disorders.

Observation:

  • A case study detailing a patient presenting with ataxia.
  • Supportive genetic studies identified a mutation in the tocopherol (alpha) transfer protein gene (TTPA).
  • The patient exhibited symptoms consistent with isolated vitamin E deficiency.

Findings:

  • Confirmed a link between TTPA gene mutations and ataxia.
  • Demonstrated that isolated vitamin E deficiency can manifest as progressive ataxia.
  • Highlighted the importance of measuring serum vitamin E levels in pediatric ataxia evaluations.

Implications:

  • Suggests routine serum vitamin E testing for children with unexplained progressive ataxia.
  • Emphasizes the potential for early vitamin E supplementation to halt or reverse neurological decline.
  • Underscores the role of genetic testing in diagnosing neurodegenerative disorders related to vitamin metabolism.

More Related Videos

Label-Free Non-Linear Optics for the Study of Tubulin-Dependent Defects in Central Myelin08:07

Label-Free Non-Linear Optics for the Study of Tubulin-Dependent Defects in Central Myelin

Published on: March 24, 2023

Fingerprinting Cardiolipin in Leukocytes by Mass Spectrometry for a Rapid Diagnosis of Barth Syndrome06:48

Fingerprinting Cardiolipin in Leukocytes by Mass Spectrometry for a Rapid Diagnosis of Barth Syndrome

Published on: March 23, 2022

Related Concept Videos

Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Huntington Disease l: Introduction01:21

Huntington Disease l: Introduction

Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show reduced penetrance,...
Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...